| Reference |
|---|
Zhang W, Chua B, Selva K, Kedzierski L, Ashhurst T, Haycroft E, et al. SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. Nat Commun. 2022;13:2774 pubmed publisher |
Machcińska M, Kierasińska M, Michniowska M, Maruszewska Cheruiyot M, Szewczak L, Rola R, et al. Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS. Int J Mol Sci. 2022;23: pubmed publisher |
Chou C, Hua K, Chen M, Wu C, Hsu C, Wang J, et al. Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6Rα to inhibit IL-6/ IL-6Rα/gp130 hexameric signaling complex formation. MAbs. 2022;14:2029675 pubmed publisher |
Zhang W, Chua B, Selva K, Kedzierski L, Ashhurst T, Haycroft E, et al. Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity. Res Sq. 2021;: pubmed publisher |
Georgieva E, Leber S, Wex C, Garbers C. Perturbation of the Actin Cytoskeleton in Human Hepatoma Cells Influences Interleukin-6 (IL-6) Signaling, but Not Soluble IL-6 Receptor Generation or NF-κB Activation. Int J Mol Sci. 2021;22: pubmed publisher |
Flynn C, Kespohl B, Daunke T, Garbers Y, Düsterhöft S, Rose John S, et al. Interleukin-6 controls recycling and degradation, but not internalization of its receptors. J Biol Chem. 2021;296:100434 pubmed publisher |
Flynn C, Garbers Y, Düsterhöft S, Wichert R, Lokau J, Lehmann C, et al. Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro. Sci Rep. 2020;10:21612 pubmed publisher |
Werner Klein M, Grujovic A, Irlbeck C, Obradovic M, Hoffmann M, Koerkel Qu H, et al. Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency. Nat Commun. 2020;11:4977 pubmed publisher |
Gupta S, Junquera G, Nicassio L, Becknell B, Ching C. Trans IL-6 signaling does not appear to play a role in renal scarring after urinary tract infection. J Pediatr Urol. 2020;16:586-591 pubmed publisher |
Flynn C, Garbers Y, Lokau J, Wesch D, Schulte D, Laudes M, et al. Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling. Sci Rep. 2019;9:7306 pubmed publisher |
Prenissl N, Lokau J, Rose John S, Haybaeck J, Garbers C. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage. Cytokine. 2019;114:1-5 pubmed publisher |
Arcidiacono P, Webb C, Brooke M, Zhou H, Delaney P, Ng K, et al. p63 is a key regulator of iRHOM2 signalling in the keratinocyte stress response. Nat Commun. 2018;9:1021 pubmed publisher |
Dogan M, Shields B, Cutrona C, Gao L, Gibbons F, SIMONS R, et al. The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women. BMC Genomics. 2014;15:151 pubmed publisher |
Richards F, Tape C, Jodrell D, Murphy G. Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS ONE. 2012;7:e40597 pubmed publisher |
Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010;116:1460-8 pubmed publisher |
Zhao S, Gu Y, Dong Q, Fan R, Wang Y. Altered interleukin-6 receptor, IL-6R and gp130, production and expression and decreased SOCS-3 expression in placentas from women with pre-eclampsia. Placenta. 2008;29:1024-8 pubmed publisher |
Ahmed S, Marotte H, Kwan K, Ruth J, Campbell P, Rabquer B, et al. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc Natl Acad Sci U S A. 2008;105:14692-7 pubmed publisher |
Briso E, Dienz O, Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol. 2008;180:7102-6 pubmed |
Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008;141:598-606 pubmed publisher |
